Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 01:14PM EST. Market open.
| Previous close | 287.52 |
| Open | 288.57 |
| Bid | 285.04 x 900 |
| Ask | 285.17 x 2200 |
| Day's range | 283.89 - 291.01 |
| 52-week range | 187.16 - 311.88 |
| Volume | |
| Avg. volume | 1,206,619 |
| Market cap | 41.751B |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | 14.73 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
Why the FDA's Rejection of Eli Lilly's Alzheimer's Drug Is Actually Great News for the Stock
When the Food and Drug Administration (FDA) rejects a key drug from a healthcare company, it can send the stock spiraling into a sell-off. In order for the FDA to be confident in a drug's effectiveness, it needs to have a large enough sample size to evaluate it. Unfortunately, in Eli Lilly's case, it simply didn't have enough data points for the agency to make a positive conclusion about the treatment and grant it accelerated approval.
- Zacks
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.
- Zacks
Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.
© 2023 Yahoo. All rights reserved.
